Drug Profile
Research programme: cancer vaccine - Inovio Pharmaceuticals/AstraZeneca
Latest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator Inovio Pharmaceuticals
- Developer AstraZeneca; Inovio Pharmaceuticals
- Class Cancer vaccines; DNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for research development in Cancer in USA
- 10 Aug 2015 MedImmune enters into collaboration with Inovio Pharmaceuticals for the development and commercialisation of vaccines for Cancer
- 10 Aug 2015 Early research in Cancer in USA (unspecified route)